{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
m nalidixic acid
to a specific field?
Status:
Investigational
Source:
NCT01755650: Early Phase 1 Interventional Terminated Squamous Cell Carcinoma
(2011)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT02965885: Phase 1 Interventional Completed Advanced Solid Tumors
(2017)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
TAS-116 is a highly potent oral HSP90 inhibitor with unique tissue distribution properties. TAS-116 has the potential to demonstrate antitumor activity, while being designed to limit certain adverse events by unique tissue distribution. Phase-II clinical trials in gastrointestinal stromal tumours are ongoing in Japan.
Status:
Investigational
Source:
NCT01714960: Phase 1 Interventional Completed Healthy Volunteers and Glaucoma Patients
(2012)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
GAL 101 (formerly MRZ 99030 or EG-030) a small-molecule β-amyloid (Aβ) aggregation modulator with neuroprotective activity. It does not directly prevent early protein/protein interactions between monomeric Aβ, but rather promotes the formation of large, non-amyloidogenic, amorphous Aβ aggregates and thereby reduces the amount of intermediate toxic soluble oligomeric Aβ species. In vivo studies demonstrate the neuroprotective potential of MRZ-99030 after systemic and topical administration in animal models of Alzheimer's disease and glaucoma and age-related macular degeneration respectively. Currently, it is in Phase I trial for the treatment of glaucoma.
Status:
Investigational
Source:
NCT02005991: Phase 1 Interventional Completed Healthy
(2013)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT03593421: Phase 2 Interventional Withdrawn Panel Reactive Antibodies
(2019)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT04399538: Phase 2 Interventional Completed Nonalcoholic Steatohepatitis
(2020)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT02772861: Not Applicable Interventional Completed Intestinal Diseases
(2011)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT01826773: Phase 2 Interventional Completed Coronary Artery Disease
(2013)
Source URL:
Class (Stereo):
CHEMICAL (MIXED)
Status:
Investigational
Source:
INN:nanvuranlat [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT01393652: Phase 1 Interventional Completed Healthy Volunteers
(2011)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
